These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30221062)

  • 1. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.
    Berntsson J; Eberhard J; Nodin B; Leandersson K; Larsson AH; Jirström K
    Oncoimmunology; 2018; 7(8):e1465165. PubMed ID: 30221062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study.
    Berntsson J; Svensson MC; Leandersson K; Nodin B; Micke P; Larsson AH; Eberhard J; Jirström K
    Int J Cancer; 2017 Oct; 141(8):1654-1666. PubMed ID: 28677162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    BMC Cancer; 2019 Feb; 19(1):142. PubMed ID: 30755167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.
    Campedel L; Compérat E; Cancel-Tassin G; Varinot J; Pfister C; Delcourt C; Gobet F; Roumiguié M; Patard PM; Daniel G; Bigot P; Carrouget J; Eymerit C; Larré S; Léon P; Durlach A; Ruffion A; de Mazancourt ES; Decaussin-Petrucci M; Bessède T; Lebacle C; Ferlicot S; Robert G; Vuong NS; Philip M; Crouzet S; Matillon X; Mège-Lechevallier F; Lang H; Mouracade P; Lindner V; Gougis P; Cussenot O; Rouprêt M; Seisen T
    BJU Int; 2023 Nov; 132(5):581-590. PubMed ID: 37488983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients: an impact on outcome.
    El Dein Mohameda AS; El-Rebey HS; AboElnasr LSA; Abdou AG
    Ecancermedicalscience; 2021; 15():1323. PubMed ID: 35047074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
    Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
    Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.
    Wei XL; Wu QN; Chen DL; Zeng ZL; Lu JB; Liu ZX; Ju HQ; Ren C; Pan ZZ; Wang FH; Xu RH
    J Cancer; 2018; 9(23):4325-4333. PubMed ID: 30519336
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
    Yang L; Xue R; Pan C
    Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
    Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
    Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 16. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3
    Karjula T; Elomaa H; Niskakangas A; Mustonen O; Puro I; Kuopio T; Ahtiainen M; Mecklin JP; Seppälä TT; Wirta EV; Sihvo E; Väyrynen JP; Yannopoulos F; Helminen O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
    Ho HL; Chou TY; Yang SH; Jiang JK; Chen WS; Chao Y; Teng HW
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1785-1794. PubMed ID: 31129768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
    Bae SB; Cho HD; Oh MH; Lee JH; Jang SH; Hong SA; Cho J; Kim SY; Han SW; Lee JE; Kim HJ; Lee HJ
    J Breast Cancer; 2016 Sep; 19(3):242-251. PubMed ID: 27721873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer.
    Berntsson J; Nodin B; Eberhard J; Micke P; Jirström K
    Int J Cancer; 2016 Sep; 139(5):1129-39. PubMed ID: 27074317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.